Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2021-12-06 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchase transactions, dates, quantities, and prices, as well as confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchases and changes in issued shares, which aligns with disclosures about transactions in the company's own shares. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a report publication announcement but a detailed disclosure of share repurchase activity. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2021-12-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares with dates, quantities, and prices, as well as confirmations that these repurchases comply with listing rules. The document references the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. It is a regulatory disclosure about share repurchases, not a financial report or earnings release. It is not a report publication announcement since it contains substantive data about share repurchases. The content fits the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares.
2021-12-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 November 2021. It details movements in authorized and issued shares, share options, repurchases, and other share capital changes. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing of share capital movements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-03 English
EXCHANGE NOTICE - RESUMPTION OF TRADING
Regulatory Filings Classification · 95% confidence The document is a short notice from the Hong Kong Stock Exchange (HKEX) regarding the resumption of trading for a specific stock code. It does not contain financial statements, management discussions, or other substantive reports. As it is a brief regulatory announcement regarding trading status, it falls under the general regulatory filings category.
2021-12-03 English
ANNOUNCEMENT - INSIDE INFORMATION - INCLUSION IN NEW CATALOGUE OF CHINA NATIONAL REIMBURSEMENT DRUG LIST (NRDL) OF ASCLEVIR/GANOVO REGIMEN, AN ALL-ORAL DIRECT ANTI-HCV THERAPY AND RESUMPTION OF
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding the inclusion of their drug regimen in the National Reimbursement Drug List (NRDL) in China and the resumption of trading of their shares. It is a regulatory announcement about a significant event affecting the company, specifically related to drug listing and trading status. The document is relatively short (4319 characters) and does not contain financial statements, detailed financial data, or management discussion. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a voting result, board change, or capital update. The content fits best under a general regulatory announcement category. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-12-03 English
TRADING HALT
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a trading halt on its shares pending the release of an announcement containing inside information. It is issued by the company board and is a regulatory announcement related to trading status, not a financial report or detailed filing. The document length is only 1197 characters, and it does not contain financial data, management discussion, or detailed report content. It is an official regulatory announcement about trading suspension, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-12-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.